TEM
Tempus AI, Inc. Class A Common Stock
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
286% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 21
214% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 14
62% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $46.8M
61% more funds holding
Funds holding: 96 [Q3] → 155 (+59) [Q4]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]
8.72% more ownership
Funds ownership: 25.2% [Q3] → 33.92% (+8.72%) [Q4]
18% less capital invested
Capital invested by funds: $2.12B [Q3] → $1.75B (-$374M) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
9%
upside
Avg. target
$61
27%
upside
High target
$74
55%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Morgan Stanley Tejas Savant 26% 1-year accuracy 5 / 19 met price target | 25%upside $60 | Overweight Maintained | 6 Mar 2025 |
Piper Sandler David Westenberg 49% 1-year accuracy 21 / 43 met price target | 15%upside $55 | Neutral Maintained | 4 Mar 2025 |
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target | 25%upside $60 | Neutral Maintained | 3 Mar 2025 |
Needham Ryan MacDonald 49% 1-year accuracy 41 / 84 met price target | 46%upside $70 | Buy Maintained | 25 Feb 2025 |
JP Morgan Rachel Vatnsdal 62% 1-year accuracy 8 / 13 met price target | 15%upside $55 | Neutral Downgraded | 25 Feb 2025 |
Financial journalist opinion
Based on 11 articles about TEM published over the past 30 days
Neutral
Business Wire
2 days ago
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medi.
Positive
Zacks Investment Research
1 week ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Positive
Seeking Alpha
1 week ago
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth, with the Data & Services segment growing by 44.6% YoY. FY24 revenues hit an all-time high of $693.4 million, with major agreements signed and the launch of the AI-enabled health app, Olivia.
Positive
Zacks Investment Research
1 week ago
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Neutral
Zacks Investment Research
2 weeks ago
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Neutral
Business Wire
2 weeks ago
Tempus Announces Acquisition of Deep 6 AI
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches pati.
Neutral
The Motley Fool
4 weeks ago
Should Investors Buy Tempus AI Stock Right Now?
Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
Neutral
Zacks Investment Research
4 weeks ago
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Positive
The Motley Fool
4 weeks ago
Tempus AI Stock Has Soared 108% Already in 2025; Is It a Buy Now?
Only time will tell if the market enthusiasm that drove artificial intelligence (AI) stocks higher in 2024 will extend through 2025. But one ticker that may be less recognizable among the AI crowd is certainly off to a roaring start since the ball fell on New Year's Eve.
Positive
Seeking Alpha
4 weeks ago
Tempus AI: Buying The Dip After 2025 Guidance Raise
Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcare AI, focuses on revenue growth and customer adoption, with a proprietary data model for personalized healthcare treatment. Despite stock volatility, Tempus AI's 30% organic revenue growth and Ambry acquisition integration highlight its long-term potential in the healthcare AI market.
Charts implemented using Lightweight Charts™